Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(60.0%)
N/A
2(40.0%)
5Total
Phase 3(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01657955Phase 3Unknown

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

Role: lead

NCT01656980Phase 3Unknown

Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma

Role: lead

NCT01572688Not ApplicableUnknown

Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma

Role: lead

NCT01570049Phase 3Unknown

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Role: lead

NCT01637753Not ApplicableUnknown

Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma

Role: lead

All 5 trials loaded